Healthcare / BiotechnologyHKSE
$8.84
-0.30 (-3.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-278.2M · quality 65.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-104.6%
↓Gross Margin
N/A
•Debt/Equity
0.53
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-299.8M · FCF $-255.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $107000.00 | — | $44.2M |
| Net Income | $-299.8M | $-299.8M | $-387.0M | $-382.4M | $-311.0M |
| EBITDA | $-266.0M | $-266.0M | $-346.0M | $-346.8M | $-292.2M |
| EPS | — | — | -1.15 | -1.03 | -0.84 |
| Gross Margin | — | — | 13.1% | — | 45.3% |
| Operating Margin | — | — | -296072.9% | — | -530.7% |
| Net Margin | — | — | -361640.2% | — | -702.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.53 | 0.53 | 0.38 | -0.05 | -0.11 |
| Current Ratio | 1.43 | 1.43 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-255.2M | $-255.2M | $-381.9M | $-278.2M | $-308.2M |
| Returns | |||||
| ROE | -104.6% | -104.6% | -82.5% | 43.2% | 61.5% |
| Valuation | |||||
| P/B | 11.72 | 11.72 | 34.55 | — | — |
| Growth & Yield | |||||
| EPS Growth | — | — | -11.5% | -23.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-59.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.15 → n/d
Residual
-59.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.